ORAGENICS INC 8-K

What Happened

• On May 7, 2026, Oragenics, Inc. (OGEN) filed a Form 8-K (Item 8.01) announcing it has signed a Letter of Intent (LOI) with Sigyn Therapeutics, Inc. to license CardioDialysis™, an extracorporeal blood‑purification technology intended to clear a broad range of inflammatory and pathogenic molecules from the bloodstream. The company attached a press release to the filing (Exhibit 99.1).

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 8.01).
• Parties: Oragenics, Inc. and Sigyn Therapeutics, Inc.
• Technology: CardioDialysis™ — extracorporeal blood purification for broad‑spectrum clearance of inflammatory and pathogenic molecules.
• Current status: LOI signed; the 8-K does not disclose financial terms or a definitive/licensing agreement.

Why It Matters

• The LOI signals a potential strategic move for Oragenics to expand into or commercialize blood‑purification technology, which could lead to future licensing revenue or partnerships if a definitive agreement is reached. However, the filing contains no financial details and does not confirm a binding license; investors should watch for follow‑up disclosures (e.g., definitive agreements or material financial terms) before assuming any impact on revenue or valuation.